Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Abstract There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significant disease control rate, we aimed to eval...
Gardado en:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Portfolio
2021-03-01
|
| Series: | Scientific Reports |
| Acceso en liña: | https://doi.org/10.1038/s41598-021-86482-x |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|